Last update 21 Nov 2024

Tebentafusp

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
Monoclonal T cell receptor anti-CD3 scFv fusion protein, Tebentafusp-TEBN
+ [5]
Mechanism
CD3 modulators(T cell surface glycoprotein CD3 modulators), gp100 modulators(Melanocyte protein PMEL modulators)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (25 Jan 2022),
RegulationFast Track (US), Orphan Drug (EU), Priority Review (AU), Breakthrough Therapy (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Melanoma
CA
07 Jun 2022
Uveal Melanoma
US
25 Jan 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 3
FR
19 Dec 2022
MelanomaPhase 3
PL
19 Dec 2022
MelanomaPhase 3
DE
19 Dec 2022
MelanomaPhase 3
BE
19 Dec 2022
MelanomaPhase 3
US
19 Dec 2022
MelanomaPhase 3
AU
19 Dec 2022
MelanomaPhase 3
CH
19 Dec 2022
MelanomaPhase 3
IT
19 Dec 2022
MelanomaPhase 3
AT
19 Dec 2022
MelanomaPhase 3
ES
19 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
dyoijppqhz(hwoyixpkgp) = Pigment dispersion was detected in the anterior chamber, iridocorneal angle, and preretinal area, along with vitiligo, leukotrichia, and cutaneous rash. Pigment dispersion progressively worsened, particularly preretinally, with a decrease in visual acuity from 0.4 to 0.2 (decimal scale). Due to clinical progression of metastases, the decision was made to discontinue tebentafusp treatment. Currently, pigment dispersion persists in the anterior chamber, affecting over 270 degrees of the angle, on the intraocular lens, and preretinally, with stability noted since the end of treatment. plskxmasxl (xodeqywfvm )
-
19 Sep 2024
Not Applicable
-
(gkoqfvtmxe) = oefdoxzxow zqwjrfmhkw (nlohekggdm )
-
14 Sep 2024
Phase 2
Uveal Melanoma
...
127
(nmjosttbbs) = ixaarybqpu xncsrbzlft (pukrrphzso )
Positive
24 May 2024
Not Applicable
-
26
wymyzvudke(jqenpidxgt) = atnnweclcl tpeyluetia (zwdnrroqmg, 22 - 610)
Positive
24 May 2024
Phase 3
Uveal Melanoma
HLA-A*02:01-positive
-
ocybownsvw(nyttiaqonb) = 2% in the tebentafusp group and 5% in the control group svoxryfhrx (ufaomzruug )
Positive
14 Dec 2023
Pembrolizumab
ESMO2023
ManualManual
Not Applicable
36
(oitqrcaqgq) = xbsfbekzms ffsrrhfbhz (ggvoclqkjt )
Positive
22 Oct 2023
Phase 3
60
(mmggegtzvd) = ovbyihlrkp elicrflvbk (qtubbbjybt )
Positive
22 Oct 2023
(Pts with detectable ctDNA at baseline)
(mmggegtzvd) = eeauptamrb elicrflvbk (qtubbbjybt )
Phase 1
-
Tebentafusp + Durvalumab with or without Tremelimumab
pwytsoustp(ujzendrigj) = brspiwvvct drwnttmsco (uggexdqenk )
-
22 Oct 2023
Phase 3
Uveal Melanoma
First line
378
(iqujjekohy) = mkpetrubuh rphcbsqtyu (sjzdxhkjul, 22 - 33)
Positive
21 Oct 2023
Investigator's choice (pembrolizumab, ipilimumab or dacarbazine)
(iqujjekohy) = notytbrhiq rphcbsqtyu (sjzdxhkjul, 11 - 25)
Phase 1
85
Tebentafusp+Durvalumab
qyjqnvlfrn(ychiyygiil) = miyfjqthes ztvekndinw (cnodyieqps, 67 - 80)
-
01 Jun 2023
Tebentafusp+Durvalumab+Tremelimumab
qyjqnvlfrn(ychiyygiil) = ycvetsnfih ztvekndinw (cnodyieqps, 70 - 81)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free